Alnylam Pharmaceuticals Inc
ALNY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$691.00 | Hpkcmhw | Nfhwdmfzg |
Alnylam Earnings: Strong Demand for Amvuttra Drives Sales; Shares Undervalued
Alnylam reported solid third-quarter results highlighted by $313 million in net product revenue, representing a 35% year-over-year increase. Alnylam’s results are largely tracking our expectations, and we maintain our fair value estimate of $199 per share. We view shares as undervalued, currently trading about 15% below our fair value estimate.